Option Care Health, Inc. (NASDAQ:OPCH) Q4 2022 Earnings Conference Call February 23, 2022 8:30 AM ET

Company Participants

Michael Shapiro - CFO & SVP

John Rademacher - CEO, President & Director

Conference Call Participants

David MacDonald - Truist Securities

Matthew Larew - William Blair

Lisa Gill - JPMorgan

Pito Chickering - Deutsche Bank

Jamie Perse - Goldman Sachs

Joanna Gajuk - Bank of America

Operator

Hello, and thank you for standing by. Welcome to Option Care Health Fourth Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions]

I would now like to hand the conference over to your speaker for today, Mike Shapiro. Sir, you may begin.

Michael Shapiro

Good morning. Please note that today's discussion will include certain forward-looking statements that reflect our current assumptions and expectations, including those related to our future financial performance and industry and market conditions. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our expectations. We encourage you to review the information in today's press release as well as in our Form 10-K filed with the SEC regarding the specific risks and uncertainties.

We do not undertake any duty to update any forward-looking statements, except as required by law. During the call, we will use non-GAAP financial measures when talking about the company's performance and financial condition. You can find additional information on these non-GAAP measures in this morning's press release posted on the Investor Relations portion of our website.

And with that, I'll turn the call over to John Rademacher, Chief Executive Officer.

John Rademacher

Thanks, Mike, and good morning, everyone. As we reported in this morning's press release, the Option Care Health team delivered another very solid quarter of results in the fourth quarter. Despite ongoing challenges on many fronts that we'll discuss on this morning's call, the team was relentlessly focused on delivering extraordinary care to the thousands of patients who rely on us every single day.

And reflecting on 2022 as a whole, I am humbled by the dedication of the team and honored by the progress we've made over the last year to advance in our mission to help transform health care by providing unsurpassed care and superior clinical outcomes in the home or ambulatory setting.

During 2022, we continue to expand our relationships with payers, providers and biopharma to offer the highest quality care at the most appropriate cost. And over this time period, we provided care to over 265,000 unique patients and their family. As always, Mike will provide a more granular overview of the results. But in Q4, we generated revenue growth of over 10%, with balanced growth coming from both our acute therapies that grew in the mid-single digits and double-digit chronic therapy growth.